Veradermics Raises $150 Million In Series C

Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men

NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct 16, 2025-

Veradermics Raises $150 Million In Series C

Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common dermatologic conditions, announced today the completion of an oversubscribed $150 million Series C financing. The financing was designed to support the registrational development and planned New Drug Application submission for Veradermics’ lead investigational product, VDPHL01, the potent…